Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial.

@article{Maffi2014CalcineurinII,
  title={Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial.},
  author={Paola Maffi and Thierry Berney and Rita Nano and Nadja Niclauss and Domenico Bosco and Raffaella Melzi and Alessia Mercalli and Paola Magistretti and Francesco de Cobelli and Manuela Battaglia and Marina Scavini and Sandrine Demuylder-Mischler and Antonio Secchi and Lorenzo Piemonti},
  journal={Transplantation},
  year={2014},
  volume={98 12},
  pages={1301-9}
}
BACKGROUND Our final objective is to develop an adoptive therapy with tolerogenic donor-specific type 1 T regulatory cells for patients with type 1 diabetes undergoing islet transplantation. The achievement of this objective depends on the availability of an immunosuppressive treatment compatible with the survival, function, and expansion of type 1 T regulatory cells. METHODS For this purpose, we designed a single-group, phase 1 to 2 trial with an immunosuppression protocol including: (i… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2013

Similar Papers

Loading similar papers…